RxDoctor Payments Data

Julia Harris, MD

Family Medicine · Naples, FLNPI 1750315107

Payments from drug & device makers

$9,122in general payments, 2019–2025

Across 465 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$1K
  • GSK$635
  • Lilly USA, LLC$630
  • Pfizer$555
  • AstraZeneca$555
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$9,117100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,122 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$695,627
Medicare patients
1,035
Services billed
11,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol21$22,891
JardianceEmpagliflozin22$22,591
EliquisApixaban16$19,904
XareltoRivaroxaban16$18,483
LivaloPitavastatin Calcium26$12,382
TrulicityDulaglutide12$11,067
NexlizetBempedoic Acid/Ezetimibe13$5,338
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$4,530
Rosuvastatin Calcium284$4,332
Lansoprazole12$3,178
Ezetimibe66$2,793
SynthroidLevothyroxine Sodium30$2,592
Niacin ErNiacin18$2,328
ValacyclovirValacyclovir Hcl28$1,585
Bupropion XlBupropion Hcl52$1,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$555$22,89121 claims
Boehringer IngelheimJardiance$1,063$22,59122 claims
PfizerEliquis$555$19,90416 claims
Johnson & JohnsonXarelto$474$18,48316 claims
Kowa Pharmaceuticals America, Inc.Livalo$529$12,38226 claims
Lilly USA, LLCTrulicity$630$11,06712 claims
Esperion Therapeutics, Inc.Nexlizet$85$5,33813 claims
AbbVieSynthroid$232$2,59230 claims
Almatica Pharma LLCSertraline Hcl$16$890139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →